Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 12/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 11/20 | 0.46 |
| ▸ | CDK2 | P24941 | 11/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 11/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.40 |
| ▸ | KHK | P50053 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6894431 | 0.90 | CHEK1 (0.44) | CHEK1CCNA2CDK2CCNA1IRAK4 | |
| SCHEMBL6895987 | 0.88 | CHEK1 (0.46) | CHEK1CCNA2CDK2CCNA1IRAK4 | |
| SCHEMBL7879179 | 0.86 | CHEK1 (0.48) | CHEK1CCNA2CDK2CCNA1IRAK4 | |
| SCHEMBL11930901 | 0.82 | CHEK1 (0.52) | CHEK1CCNA2CDK2CCNA1IRAK4 | |
| SCHEMBL6894483 | 0.81 | EGFR (0.40) | CHEK1CCNA2CDK2CCNA1FFAR4 | |
| SCHEMBL6894438 | 0.81 | CHEK1 (0.46) | CHEK1CCNA2CDK2CCNA1RET | |
| SCHEMBL6893387 | 0.79 | CHEK1 (0.49) | CHEK1CCNA2CDK2CCNA1FFAR4 | |
| SCHEMBL7874772 | 0.78 | CHEK1 (0.57) | CHEK1CCNA2CDK2CCNA1IRAK4 | |
| SCHEMBL14543125 | 0.78 | CHEK1 (0.54) | CHEK1CCNA2CDK2CCNA1IRAK4 | |
| SCHEMBL16784467 | 0.77 | BTK (0.47) | CHEK1CCNA2CDK2CCNA1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20110054013-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054013-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | BACE1, BACE2, PSEN1 | CHEK1 2755/4885CCNA2 2265/4885CDK2 457/4885 |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | CHEK1 461/4885CCNA2 2476/4885CDK2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.